Add this topic to your myFT Digest for news straight to your inbox
Their outlook may be traditional but that does not mean shareholders are wrong
Hokugo to stress dangers of cross-holdings and ‘allegiants’ hidden in registers
Dissident group has little actual clout but carries influence of founding family members
Christophe Weber says focus on orphan drugs will help combined group in ‘tougher’ environment
Pharma group backs offer from Japanese rival after rejecting four previous bids
The seven stages of grief when an asset management contract is terminated
Deutsche Bank trims US operations; Shire, WhatsApp, SoftBank and Capita in the news
Moves highlight new potential hypocrisies for dealing with cross-border transactions
Analysts say Japanese drugmaker has few alternatives left if it is to compete globally
Japanese company to join top ranks of global pharma groups
Only low Japanese interest rates make the numbers work in this deal
Japanese company makes its biggest bet to join the top ranks of global pharma groups
Takeda’s offer to pay $65bn for Shire comes amid a rush of M&A deals in healthcare
UK rare diseases drug company had rebuffed three previous proposals
Japanese pharma group’s latest proposal includes higher cash component
Shares in Irish drugmaker yo-yo as US group says it may also bid, then pulls out
To back the bid, investors must believe it can cut costs and promote faster growth
Deal may make Irish drugmaker less attractive to Takeda, which has been eyeing bid
Takeda considers Shire bid, Waymo and JLR pair up, Carlyle and Remington’s last shot
More than half of acquisitions in the first quarter were worth in excess of $5bn
International Edition